Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting resources
  3. ESMO Targeted Anticancer Therapies Congress

Daiichi Sankyo/AstraZeneca - From bench to bedside and back to bench: The evolution of antibody–drug conjugates in the treatment of cancer

Introduction

Date

07 Mar 2022

Session

Daiichi Sankyo/AstraZeneca - From bench to bedside and back to bench: The evolution of antibody–drug conjugates in the treatment of cancer

Topics

Targeted Therapy

Tumour Site

Presenters

Solange Peters

Authors

S. Peters

Author affiliations

  • CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne/CH
More

Resources

Login to access the resources on OncologyPRO.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.